HC Wainwright Reaffirms “Buy” Rating for Phio Pharmaceuticals (NASDAQ:PHIO)

HC Wainwright reiterated their buy rating on shares of Phio Pharmaceuticals (NASDAQ:PHIOFree Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q2 2024 earnings at ($0.51) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($1.82) EPS and FY2025 earnings at $3.78 EPS.

Phio Pharmaceuticals Stock Up 7.4 %

Shares of PHIO stock opened at $0.79 on Tuesday. The stock has a 50 day moving average of $0.77 and a 200-day moving average of $0.82. The firm has a market cap of $3.61 million, a PE ratio of -0.24 and a beta of 1.36. Phio Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $6.85.

Phio Pharmaceuticals (NASDAQ:PHIOGet Free Report) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.17) earnings per share (EPS) for the quarter. As a group, equities analysts predict that Phio Pharmaceuticals will post -1.82 EPS for the current fiscal year.

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.

Read More

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.